| 1. |
- Villa, Luisa L., et al.
(author)
-
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
- 2007
-
In: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 356:19, s. 1915-1927
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18. METHODS: In this randomized, double-blind trial, we assigned 12,167 women between the ages of 15 and 26 years to receive three doses of either HPV-6/11/16/18 vaccine or placebo, administered at day 1, month 2, and month 6. The primary analysis was performed for a per-protocol susceptible population that included 5305 women in the vaccine group and 5260 in the placebo group who had no virologic evidence of infection with HPV-16 or HPV-18 through 1 month after the third dose (month 7). The primary composite end point was cervical intraepithelial neoplasia grade 2 or 3, adenocarcinoma in situ, or cervical cancer related to HPV-16 or HPV-18. RESULTS: Subjects were followed for an average of 3 years after receiving the first dose of vaccine or placebo. Vaccine efficacy for the prevention of the primary composite end point was 98% (95.89% confidence interval [CI], 86 to 100) in the per-protocol susceptible population and 44% (95% CI, 26 to 58) in an intention-to-treat population of all women who had undergone randomization (those with or without previous infection). The estimated vaccine efficacy against all high-grade cervical lesions, regardless of causal HPV type, in this intention-to-treat population was 17% (95% CI, 1 to 31). CONCLUSIONS: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV-16 or HPV-18 than did those in the placebo group.
|
|
| 2. |
- Johannisson, Jenny, et al.
(author)
-
Vetenskap på tvären : akademiska värden, friheter och gränser
- 2013
-
In: Vetenskap för profession. - : Högskolan i Borås. - 1654-6520. ; :26, s. 11-19
-
Journal article (other academic/artistic)abstract
- Texten utgör en inledning till antologin Vetenskap på tvären; den tredje volymen som dokumenterar seminarieserien Från Högskolan i Borås till Humboldt. Texten sätter den tredje seminarieseriens innehåll i förhållande till de två tidigare, diskuterar i korthet några aspekter på begreppet och företeelsen tvärvetenskap samt introducerar de nio övriga uppsatser som ingår i volymen.
|
|
| 3. |
- Björnelius, E, et al.
(author)
-
Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial.
- 2008
-
In: Sexually transmitted infections. - : BMJ. - 1472-3263 .- 1368-4973. ; 84:1, s. 72-6
-
Journal article (peer-reviewed)abstract
- OBJECTIVES: To evaluate the microbiological cure rate after treatment with tetracyclines or azithromycin in patients infected with M genitalium. METHODS: One hundred and fifty-two men and 60 women positive for M genitalium were recruited. Patients treated either with doxycyline for 9 days or with azithromycin 1 g stat. were compared. Those still positive for M genitalium after primary doxycycline treatment received an extended course of azithromycin 500 mg on day 1 followed by 250 mg daily for the following 4 days, whereas those with treatment failure after azithromycin received doxycycline 100 mg twice daily for 15 days. RESULTS: The eradication rate after azithromycin 1 g stat. was 85% (95% CI 69 to 94) in men (n = 39) and 88% (95% CI 64 to 99) in women (n = 17) and after doxycycline 17% (95% CI 9 to 27) in men (n = 76) and 37% (95% CI 19 to 58) in women (n = 27). Extended azithromycin eradicated M genitalium from 96% (95% CI 85 to 99) of the men (n = 47) and from all six women who failed on doxycycline. Extended doxycycline treatment was insufficient. Persistent urethral inflammation was seen in a substantial portion of the men after eradication of M genitalium regardless of the antibiotic drug, indicating a poor predictive value of urethral smears in evaluation of persistent or recurrent infection. CONCLUSIONS: Azithromycin was more effective than doxycycline in treating patients infected with M genitalium. The extended course of azithromycin was highly effective but was given after the initial treatment with doxycycline. Randomised clinical trials are needed to compare the different dosages of azithromycin.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Erikson, Martin G, et al.
(author)
-
Från Högskolan i Borås till Humboldt, volym 3
- 2013
-
Reports (other academic/artistic)abstract
- Denna rapport är den tredje i ordningen som har sin upprinnelse i Humboldtuniversitetets 200-årsjubileum och i ambitionen att föra en kvalificerad diskussion om vilka roller som högskolor och universitet spelar idag. Rapporten ägnar särskild uppmärksamhet åt fenomenet tvärvetenskap och de utmaningar som en sådan ansats innebär, men den för också upp grundläggande principfrågor om akademiska friheter och värden till diskussion.
|
|
| 7. |
|
|
| 8. |
- Gisslén, Magnus, 1962, et al.
(author)
-
Sexuellt överförbara sjukdomar
- 2005
-
In: Läkemedelsboken 2005/2006. ; , s. 387-398
-
Book chapter (other academic/artistic)
|
|
| 9. |
- Gisslén, Magnus, 1962, et al.
(author)
-
Sexuellt överförbara sjukdomar
- 2007
-
In: Läkemedelsboken 2007/2008. ; , s. 399-408
-
Book chapter (other academic/artistic)
|
|
| 10. |
- Gisslén, Magnus, 1962, et al.
(author)
-
Sexuellt överförbara sjukdomar
- 2009
-
In: Läkemedelsboken 2009/2010. ; , s. 427-438
-
Book chapter (other academic/artistic)
|
|
